Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin^®)

Purpose To report a case of contralateral vitritis following intravitreal bevacizumab (Avastin^®, Roche Pharma). Case summary A 54-year-old man was treated with intravitreal bevacizumab (IB) for a choroidal neovascularization secondary to anisometropic high myopia in the right eye that did not respond to photodynamic treatment. After the second injection, he showed a moderate vitritis in the fellow un-injected eye a few hours later. Results The patient was treated with a sub-Tenon’s injection of 40 mg triamcinolone (Kenacort^®, Squibb) and entirely recovered his vision. No further complications were observed. Discussion Although IB has a satisfactory safety profile, the possibility of unusual complications associated with the drug or the procedure itself should always be considered.